The m 6 A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis

Yongqiang Zhou,Jiexi Yan,He Huang,Lu Liu,Longfei Ren,Jinjing Hu,Xiaoxu Jiang,Yan Zheng,Lingcong Xu,Fupeng Zhong,Xun Li

DOI: https://doi.org/10.1038/s41419-024-06509-9

2024-03-06

Cell Death and Disease

Abstract:Evidence for the involvement of N 6 -Methyladenosine (m 6 A) modification in the etiology and progression of liver fibrosis has emerged and holds promise as a therapeutic target. Insulin-like growth factor 2 (IGF2) mRNA-binding protein 2 (IGF2BP2) is a newly identified m 6 A-binding protein that functions to enhance mRNA stability and translation. However, its role as an m 6 A-binding protein in liver fibrosis remains elusive. Here, we observed that IGF2BP2 is highly expressed in liver fibrosis and activated hepatic stellate cells (HSCs), and inhibition of IGF2BP2 protects against HSCs activation and liver fibrogenesis. Mechanistically, as an m 6 A-binding protein, IGF2BP2 regulates the expression of Aldolase A ( ALDOA ), a key target in the glycolytic metabolic pathway, which in turn regulates HSCs activation. Furthermore, we observed that active glycolytic metabolism in activated HSCs generates large amounts of lactate as a substrate for histone lactylation. Importantly, histone lactylation transforms the activation phenotype of HSCs. In conclusion, our findings reveal the essential role of IGF2BP2 in liver fibrosis by regulating glycolytic metabolism and highlight the potential of targeting IGF2BP2 as a therapeutic for liver fibrosis.

cell biology

What problem does this paper attempt to address?

The paper primarily explores the role of N6-methyladenosine (m6A) modification in the pathogenesis of liver fibrosis, with a particular focus on the impact of insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) as an m6A-binding protein on the activation of hepatic stellate cells (HSCs) and the progression of liver fibrosis.

The main findings of the paper can be summarized as follows:
1. **Upregulation of IGF2BP2 in liver fibrosis**: Researchers first observed that the expression level of IGF2BP2 is elevated in various liver fibrosis models, and this elevated expression is positively correlated with the severity of liver fibrosis.
2. **Protective role of IGF2BP2 in liver fibrosis**: Experiments in mouse models revealed that inhibiting IGF2BP2 can alleviate carbon tetrachloride (CCl4)-induced liver fibrosis, suggesting that IGF2BP2 may be a potential therapeutic target for liver fibrosis.
3. **IGF2BP2 regulates glycolytic metabolism**: Further mechanistic studies showed that IGF2BP2 regulates the glycolytic pathway by stabilizing Aldolase A (ALDOA) mRNA, a key enzyme in the glycolytic pathway.
4. **Role of lactate as a substrate for histone lactylation**: Activated HSCs produce a large amount of lactate through glycolysis, and this lactate can serve as a substrate for histone lactylation, thereby affecting the activation phenotype of HSCs.
5. **IGF2BP2 regulates histone lactylation**: IGF2BP2 indirectly affects the level of histone lactylation by regulating lactate production, which may play an important role in the activation of HSCs.

In summary, this study reveals that IGF2BP2 promotes the activation of HSCs and the occurrence and development of liver fibrosis by regulating glycolytic metabolism and histone lactylation. These findings provide new insights into the molecular mechanisms of liver fibrosis and offer a theoretical basis for developing strategies to treat liver fibrosis.